Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients’ Survival
Table 2
Median sCD30 levels according to demographic characteristics of kidney allograft recipients at baseline.
Patient’s characteristics
n
Pretransplant sCD30
value
n
Posttransplant sCD30
value
Age
21–40 ()
54.8 (36.9–96.6)
0.151
21–39 ()
21.4 (15.7–40.1)
0.817
>40 ()
42.0 (30.8–60.2)
>39 ()
23.3 (14.8–37.5)
Gender
Female ()
42.1 (29.1–71.2)
0.595
Female ()
26.6 (21.2–39.7)
0.260
Male ()
51.6 (36.2–64.2)
Male ()
18.4 (12.9–38.8)
Donor source
Living ()
85.6 (40.9–159.9)
0.038
Living ()
39.4 (30.3–45.0)
0.133
Deceased ()
48.3 (27.3–64.2)
Deceased ()
21.4 (13.4–37.6)
Donor age
17–38 ()
54.8 (36.2–70.6)
0.960
17–39 ()
21.4 (13.4–40.1)
0.709
>38 ()
45.0 (29.7–79.5)
>39 ()
25.1 (15.9–38.7)
Primary disease
GN ()
51.0 (30.8–70.7)
0.782
GN ()
22.2 (14.6–38.7)
0.643
non-GN ()
45.8 (38.8–78.4)
non-GN ()
23.5 (16.1–45.3)
Dialysis modality
HD ()
50.2 (30.8–70.7)
0.814
HD ()
21.4 (13.4–37.6)
0.075
PD ()
40.9 (40.1–88.5)
PD ()
44.8 (34.0–52.9)
Dialysis duration
≤18 m ()
50.6 (32.2–71.7)
0.711
<18 m ()
30.3 (19.2–42.5)
0.146
>18 m ()
48.3 (30.8–70.6)
≥18 m ()
19.9 (12.4–28.0)
Pregnancies
Yes ()
60.2 (40.9–70.7)
0.661
Yes ()
27.7 (16.5–45.4)
0.730
No ()
48.9 (31.5–71.1)
No ()
23.1 (15.7–39.7)
Transfusions
Yes ()
47.5 (42.0–58.2)
0.988
Yes ()
23.5 (15.7–39.7)
0.682
No ()
51.0 (27.3–72.6)
No ()
22.2 (13.4–40.1)
Previous transplants
Yes ()
57.6 (51.0–64.2)
0.618
Yes ()
20.6 (13.4–27.8)
0.689
No ()
48.3 (30.8–71.7)
No ()
23.1 (15.7–40.1)
Anti-CD25 antibodies
Yes ()
48.9 (29.1–67.4)
0.567
Yes ()
21.4 (13.4–37.4)
0.089
No ()
51.6 (40.1–72.6)
No ()
46.0 (23.5–50.7)
sCD30: soluble CD30; GN: glomerulonephritis; HD: hemodialysis; PD: peritoneal dialysis; m: months; n: number of patients investigated. Median (interquartile range); values: significance of differences between subgroups of patients.
